Pluri (NASDAQ:PLUR) Releases Earnings Results, Beats Expectations By $0.11 EPS

Pluri (NASDAQ:PLUR) announced its quarterly earnings data on Thursday. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.11, FiscalAI reports. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.66 million.

Pluri Stock Down 0.9%

Shares of NASDAQ:PLUR opened at $3.37 on Friday. The company has a market cap of $36.31 million, a price-to-earnings ratio of -0.74 and a beta of 0.75. The firm’s 50-day simple moving average is $3.35 and its 200-day simple moving average is $3.42. Pluri has a fifty-two week low of $2.82 and a fifty-two week high of $5.96.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pluri has an average rating of “Hold” and a consensus price target of $12.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new stake in shares of Pluri Inc. (NASDAQ:PLUR) in the first quarter, according to its most recent filing with the SEC. The firm purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri at the end of the most recent quarter. 16.59% of the stock is owned by institutional investors and hedge funds.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.